Celldex Therapeutics has reported positive results from its Phase I study of CDX-301 (recombinant human Flt3L; rhuFlt3L) conducted in healthy volunteers.

The positive data from the study conducted at Rockefeller University supports the commencement of a pilot study in hematopoietic stem cell transplantation.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Celldex clinical science vice president Dr Michael Yellin said CDX-301 is well-tolerated and can effectively mobilise hematopoietic stem cell populations as a single agent in healthy volunteers.

"Based on the safety profile and the impressive increases observed for CD34+ stem cells and dendritic cells, we believe CDX-301 holds significant promise in both the allogeneic and autologous transplant setting, including the potential for combination with other molecules that could work in synergy with CDX-301 to further enhance the mobilisation of hematopoietic stem cell populations," Yellin said.

"The positive data from the study conducted at Rockefeller University supports the commencement of a pilot study in hematopoietic stem cell transplantation."

"Published pre-clinical Flt3L studies also suggest that CDX-301 could potentially improve engraftment and reduce the risk of graph versus host disease. This may be especially important for older patients and patients who are in poor health."

The study enrolled 30 healthy volunteers across seven cohorts.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Escalating doses of CDX-301301 (from 1mcg/kg to 75mcg/kg) as a five-day regimen was assessed in the first five cohorts, while CDX-301 (at 25mcg/kg) was evaluated in the final two cohorts as seven and 10-day regimens.

Short-term dosing of five days produced a median of 10-fold increases in CD34+ cells. On day 10 of dosing, more than a 100-fold increase in dendritic cells was observed in the peripheral blood.

Transient grade 1 lymphadenopathy was observed in six volunteers (all treated at the highest dose levels of 25mcg/kg and 75mcg/kg), while CDX-301 was well-tolerated.

Volunteers did not exhibit any anti-CDX-301 antibodies at any time from commencement to the end of study follow-up.